Microbiome Futures: New meeting to charter course for global translation
Global Engage is partnering with Nature Biotechnology to launch the first meeting of Microbiome Futures – A Global Translational Roadmap in New York next year.
The congress, which will take place on May 23rd, 2018, will bring together key opinion leaders and will focus on laying out the technical challenges and strategic opportunities for basic science, venture capitalists, biotech and pharma to lift the field to the next level. The event will include a face-to-face roundtable discussion moderated by Susan Jones, Senior Editor at Nature Biotechnology and Gaspar Taroncher-Oldenburg, Consultant for Global Engage.
The State of the Field
Great expectations have been raised over the last two decades by advances made in unlocking the mysteries of the microbiome and by first inroads taken into harnessing the resulting scientific insights for wellness and therapeutic purposes.
The sobering reality however is that with the exception of fecal microbiota transplantation for the treatment of Clostridium difficile infection and of a handful of scientifically backed probiotics, the development of microbiome based therapeutics and wellness products – whether targeting the microbiome or using it as a source of therapeutic and prophylactic compounds – has been slow in the making because of our limited understanding of the complex biology underlying the microbiome’s function and physiology.
Hope for the Future
Despite this knowledge gap, researchers, investors and companies are increasingly coming together to devise new and creative ways in which to address the challenge.
Against this backdrop of innovation in the microbiome space, and building on its far-reaching network of key opinion leaders and its experience providing a forum for collaboration in the field, Global Engage is now poised to convene top players from academia and pharma, technology providers and the investment community to discuss and define the future of microbiome research and its potential commercialisation over the next two to four years.
This article has been republished from materials provided by Global Engage. Note: material may have been edited for length and content. For further information, please contact the cited source.
Chemicals in Lavender and Tea Tree Oil Could be Hormone DisruptorsNews
A new study lends further evidence to a suspected link between abnormal breast growth in young boys--called prepubertal gynecomastia--and regular exposure to lavender or tea tree oil, by finding that key chemicals in these common plant-derived oils act as endocrine-disrupting chemicals.READ MORE
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018